Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera - Trial NCT03882307
Access comprehensive clinical trial information for NCT03882307 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Assiut University and is currently Recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assiut University
Timeline & Enrollment
Early Phase 1
Apr 01, 2021
Sep 01, 2021
Primary Outcome
mean difference in level of interleukin-6 and transforming growth factor beta after treatment
Summary
Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality
 owing to progression of a high percentage (85%) of HCV infected patients to chronic
 hepatitis, which might lead to the development of liver cirrhosis or hepato cellular
 carcinoma..
 
 Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population
 .
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03882307
Non-Device Trial